Search

Your search keyword '"Voest, Emile"' showing total 434 results

Search Constraints

Start Over You searched for: Author "Voest, Emile" Remove constraint Author: "Voest, Emile" Database Unpaywall Remove constraint Database: Unpaywall
434 results on '"Voest, Emile"'

Search Results

1. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer

3. PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe

4. Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy

5. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)

6. Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol

15. A pan-cancer analysis of the microbiome in metastatic cancer

29. Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

31. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

32. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice

33. Impact of genetic counselling strategy on diagnostic yield and workload for genome sequencing-based tumour diagnostics

34. Precision cancer medicine: Concepts, current practice, and future developments

36. Phase II study ( KAMELEON ) of single‐agent T‐DM1 in patients with HER2 ‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma

37. Supplementary Materials and Methods from Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity

38. Data from AACR Project GENIE: Powering Precision Medicine through an International Consortium

39. Supplementary Figures 1-11 from Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity

40. Table S3 from AACR Project GENIE: Powering Precision Medicine through an International Consortium

41. Data from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

42. Supplementary Figure 4 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

43. Table S4 from AACR Project GENIE: Powering Precision Medicine through an International Consortium

44. Supplementary Figure 5 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

46. Table S4 from AACR Project GENIE: Powering Precision Medicine through an International Consortium

47. Supplementary Figure 1 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

48. Supplementary Table 1 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

49. Supplementary Table 4 from Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity

50. Supplementary Figure 3 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

Catalog

Books, media, physical & digital resources